Understanding RAD52: Potential Drug Target for Cancer (G5893)

Target Name: RAD52

NCBI ID: G5893

RAD52

Understanding RAD52: Potential Drug Target for Cancer

RAD52 is a tumor suppressor gene located on chromosome 18q21 in humans. It has been implicated in the development and progression of many types of cancer, including breast, ovarian, and prostate cancers. Despite its potential as a drug target, much is still not known about RAD52 and its role in cancer.

Expression of RAD52

RAD52 is a highly expressed gene in most human tissues, including cancer cells. It is expressed in the nuclei of human cells and is involved in the maintenance of cellular stability and the regulation of cell growth.

One of the key functions of RAD52 is its role in DNA repair. RAD52 is a transcription factor that has been shown to play a role in the repair of DNA damage caused by various mechanisms, including exposure to ionizing radiation and other forms of stress.

In addition to its role in DNA repair, RAD52 has also been shown to be involved in the regulation of cell cycle progression. It has been shown to promote the G1 phase of the cell cycle and to inhibit the S phase. This means that RAD52 helps to keep cells in a state of readiness for growth and division.

Drug targeting RAD52

Despite its potential as a drug target, much research has been done on RAD52 without much success. One reason for this is that the RAD52 gene is difficult to target with small molecules, which are often used as drug candidates.

One approach that has been explored for targeting RAD52 is the use of small molecules that can modulate its expression levels. One such approach is the use of inhibitors of DNA repair pathways, which can be used to reduce the amount of DNA damage caused by RAD52.

Another approach that has been explored is the use of small molecules that can inhibit the activity of RAD52 itself. This has been shown to be effective in reducing the growth of cancer cells that are dependent on RAD52.

Another approach that is being explored is the use of antibodies that can target RAD52 and prevent it from interacting with its downstream targets. This approach has the potential to be an effective way to target RAD52 and inhibit its activity.

Conclusion

In conclusion, RAD52 is a tumor suppressor gene that has the potential to be a drug target for cancer. Despite much research, much is still not known about its role in cancer development and progression. Further research is needed to fully understand the potential of RAD52 as a drug target and to develop effective therapies that can target it.

Protein Name: RAD52 Homolog, DNA Repair Protein

Functions: Involved in double-stranded break repair. Plays a central role in genetic recombination and DNA repair by promoting the annealing of complementary single-stranded DNA and by stimulation of the RAD51 recombinase

The "RAD52 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RAD52 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets